File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1517/14656566.5.11.2361
- Scopus: eid_2-s2.0-8544261146
- PMID: 15500383
- WOS: WOS:000224944600017
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Adefovir dipivoxil in chronic hepatitis B infection
Title | Adefovir dipivoxil in chronic hepatitis B infection |
---|---|
Authors | |
Keywords | Adefovir Adefovir dipivoxil HBV DNA Nucleotide analogue Treatment |
Issue Date | 2004 |
Publisher | Informa Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop |
Citation | Expert Opinion On Pharmacotherapy, 2004, v. 5 n. 11, p. 2361-2367 How to Cite? |
Abstract | Adefovir dipivoxil, an acyclic nucleotide analogue, is effective for the treatment of chronic hepatitis B in both hepatitis B e antigen (HBeAg)-positive and -negative patients, with improvement in liver histology, hepatitis B virus (HBV) DNA levels, alanine aminotransferase levels, and HBeAg seroconversion (for HBeAg-positive patients). It is also effective against lamivudine-resistant strains of hepatitis B mutations. It has been studied in pre- and post-liver transplant patients. Compared to lamivudine, adefovir dipivoxil is associated with a much lower risk of emergence of drug-resistant HBV. Adefovir-associated resistant virus is susceptible to lamivudine therapy. The recommended dose of adefovir dipivoxil 10 mg is associated with low risk of nephrotoxicity. Adefovir dipivoxil can be recommended as a firs-line treatment but can also be used in patients with chronic hepatitis B infection who are failing lamivudine therapy. © 2004 Ashley Publications Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/78100 |
ISSN | 2023 Impact Factor: 2.5 2023 SCImago Journal Rankings: 0.687 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yuen, MF | en_HK |
dc.contributor.author | Lai, CL | en_HK |
dc.date.accessioned | 2010-09-06T07:39:10Z | - |
dc.date.available | 2010-09-06T07:39:10Z | - |
dc.date.issued | 2004 | en_HK |
dc.identifier.citation | Expert Opinion On Pharmacotherapy, 2004, v. 5 n. 11, p. 2361-2367 | en_HK |
dc.identifier.issn | 1465-6566 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/78100 | - |
dc.description.abstract | Adefovir dipivoxil, an acyclic nucleotide analogue, is effective for the treatment of chronic hepatitis B in both hepatitis B e antigen (HBeAg)-positive and -negative patients, with improvement in liver histology, hepatitis B virus (HBV) DNA levels, alanine aminotransferase levels, and HBeAg seroconversion (for HBeAg-positive patients). It is also effective against lamivudine-resistant strains of hepatitis B mutations. It has been studied in pre- and post-liver transplant patients. Compared to lamivudine, adefovir dipivoxil is associated with a much lower risk of emergence of drug-resistant HBV. Adefovir-associated resistant virus is susceptible to lamivudine therapy. The recommended dose of adefovir dipivoxil 10 mg is associated with low risk of nephrotoxicity. Adefovir dipivoxil can be recommended as a firs-line treatment but can also be used in patients with chronic hepatitis B infection who are failing lamivudine therapy. © 2004 Ashley Publications Ltd. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Informa Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop | en_HK |
dc.relation.ispartof | Expert Opinion on Pharmacotherapy | en_HK |
dc.rights | Expert Opinion on Pharmacotherapy. Copyright © Informa Healthcare. | en_HK |
dc.subject | Adefovir | - |
dc.subject | Adefovir dipivoxil | - |
dc.subject | HBV DNA | - |
dc.subject | Nucleotide analogue | - |
dc.subject | Treatment | - |
dc.subject.mesh | Adenine - analogs & derivatives - pharmacokinetics - therapeutic use | en_HK |
dc.subject.mesh | Animals | en_HK |
dc.subject.mesh | Antiviral Agents - pharmacokinetics - therapeutic use | en_HK |
dc.subject.mesh | Clinical Trials as Topic | en_HK |
dc.subject.mesh | Drug Resistance, Viral - genetics | en_HK |
dc.subject.mesh | Hepatitis B e Antigens - blood | en_HK |
dc.subject.mesh | Hepatitis B virus - drug effects - genetics | en_HK |
dc.subject.mesh | Hepatitis B, Chronic - drug therapy - immunology | en_HK |
dc.subject.mesh | Humans | en_HK |
dc.subject.mesh | Lamivudine - therapeutic use | en_HK |
dc.subject.mesh | Phosphonic Acids - pharmacokinetics - therapeutic use | en_HK |
dc.title | Adefovir dipivoxil in chronic hepatitis B infection | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1465-6566&volume=5&issue=11&spage=2361&epage=7&date=2004&atitle=Adefovir+dipivoxil+in+chronic+hepatitis+B+infection | en_HK |
dc.identifier.email | Yuen, MF:mfyuen@hkucc.hku.hk | en_HK |
dc.identifier.email | Lai, CL:hrmelcl@hku.hk | en_HK |
dc.identifier.authority | Yuen, MF=rp00479 | en_HK |
dc.identifier.authority | Lai, CL=rp00314 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1517/14656566.5.11.2361 | en_HK |
dc.identifier.pmid | 15500383 | - |
dc.identifier.scopus | eid_2-s2.0-8544261146 | en_HK |
dc.identifier.hkuros | 101393 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-8544261146&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 5 | en_HK |
dc.identifier.issue | 11 | en_HK |
dc.identifier.spage | 2361 | en_HK |
dc.identifier.epage | 2367 | en_HK |
dc.identifier.isi | WOS:000224944600017 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Yuen, MF=7102031955 | en_HK |
dc.identifier.scopusauthorid | Lai, CL=7403086396 | en_HK |
dc.identifier.issnl | 1465-6566 | - |